Cancer Care RecipientNCT07396064
Bridging the Gap: Enhancing Cancer Care for Underserved Populations With the Veris Health Cancer Care Platform
An observational study of Cancer Care Recipient and Observational Study, run by VERIS HEALTH INC at 1 site in United States.
Trial summary
The proposed study aims to optimize and validate the Veris Cancer Care Platform for the needs of medically underserved cancer patients receiving outpatient cancer therapy. The Veris Health platform is a remote patient monitoring and communication system designed to bridge the gap between clinical visits and provide… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer Care Recipient, Observational Study
- What is being tested?
- Veris Health Inc. Application
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- 11 Mar 2026to 30 Nov 2027
- How long will I take part?
- 24 Weeks
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Underserved population undergoing Cancer treatment with at least one on the following barriers to healthcare access: Spanish as primary language, uninsured, insured with Medicaid, dual eligible for Medicare and Medicaid.
Who may be able to join
- Adults > 18 years old
- Diagnosis of cancer
- ECOG Performance Status of 0-2
- Undergoing or initiating systemic anticancer therapy
- Able to utilize and interact with a mobile application and in-home devices for physiological monitoring. Have at least one of the following barriers to healthcare access: Spanish as primary language, uninsured, insured with Medicaid, dual eligible for Medicare and Medicaid
Who cannot join
- -N/A
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
The Ohio State University
Columbus, Ohio, 43210
Raquel Reinbolt, MD, 614-293-8054, Raquel.Reinbolt@osumc.edu
About this study
The proposed study aims to optimize and validate the Veris Cancer Care Platform for the needs of medically underserved cancer patients receiving outpatient cancer therapy. The Veris Health platform is a remote patient monitoring and communication system designed to bridge the gap between clinical visits and provide oncology care teams with objective data during high-risk periods.
This study will specifically focus on optimizing the Veris Health platform for patients with language barriers, limited access to technology, and socioeconomic disparities. By incorporating user-centered design and working closely with community health centers, the research team will ensure that the platform is culturally and linguistically appropriate, easy to use, and accessible for all patients.
The study will use a mixed-methods approach to validate the effectiveness of the optimized platform, including quantitative data analysis and qualitative interviews with patients and healthcare providers. The goal is to demonstrate the potential for the Veris Health platform to improve outcomes for vulnerable populations by reducing hospitalizations, emergency department visits, and the economic burden of cancer care.
- Conditions
- Cancer Care Recipient, Observational Study
- Being tested
- Veris Health Inc. Application
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Veris Health Inc. ApplicationOther
Veris Health offers at-home devices to monitor multiple physiological parameters, including temperature, heart rate, oxygen saturation, blood pressure, weight, and activity (step count). Patients are provided with a home cellular hub that is already paired to peripheral devices via Bluetooth. The hub communicates with all devices and the local cellular network out-of-the-box, and data is automatically sent via cellular network to the Veris Health backend database, making it easy for patients to use the system. Patients are responsible for taking their vital sign measurements daily. The devices automatically send the measurement data to the Veris Health HIPAA compliant, secure cloud server via the preconnected cellular hub.
| Study group | Role | What they receive |
|---|---|---|
| Main Phase group | All participating subject utilizing the Veris Health app will complete all study health measurements with a 24 week period on the Veris Health app as well as participate in interviews and focus groups. Receives: Other: Veris Health Inc. Application |
What is being measured
The primary outcome is the main question the study is designed to answer.
Usability of the Veris Health Cancer Care Platform
Usability of the Veris Health Cancer Care platform as assessed by the Software Usability Measurement Inventory (SUMI) among patients, caretakers, and healthcare teams.
Measure: SUMI total and domain scores
Time Frame: During study participation
Measured: 5 Months
Product Design Usability and Acceptability
Ease of use, accessibility, and acceptability of the Veris Health Cancer Care platform based on A/B testing of product design features.
Measure: Comparative usability metrics (e.g., task completion success, user preference)
Time Frame: During study participation
Measured: 5 Months
User Needs and Preferences
User-identified needs, preferences, and barriers to use of the Veris Health Cancer Care platform.
Measure: Qualitative themes derived from user interviews and focus groups
Time Frame: During study participation
Measured: 5 Months
Secondary outcomes (3)
Health-Related Quality of Life (HRQL)
Change in health-related quality of life among participants using the Veris Health Cancer Care platform.
Measure: EQ-5D Index score
Measured: 5 Months
Symptom Burden of Cancer Treatment Side Effects
Frequency and severity of cancer treatment-related symptoms, including nausea, diarrhea, and infection.
Measure: Patient-reported symptom frequency and severity scores
Measured: 5 Months
Cancer Treatment Adherence and Duration
Adherence to prescribed cancer therapy and treatment duration.
Measure: Rates of dose reductions, early treatment discontinuation, and treatment duration
Measured: 5 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Feb 2026
- Study start11 Mar 2026
- Primary completion30 Nov 2027 (estimated)
- Study completion30 Nov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cancer Care RecipientStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
- Target duration
- 24 Weeks
Sponsor and investigators
- Lead sponsor
- VERIS HEALTH INC
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), The Ohio State University Comprehensive Cancer Center
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07396064
- Sponsor's protocol ID
- VER-PR-0023
- Other IDs
- 5R44MD019611-02
- Status last verified
- Sep 2026
- First submitted
- 27 Jan 2026
- Last updated
- 23 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bridging the Gap: Enhancing Cancer Care for Underserved Populations With the Veris Health Cancer Care Platform
- ClinicalTrials.gov ID
- NCT07396064
- Acronym / sponsor ID
- VER-PR-0023
- Conditions
- Cancer Care Recipient, Observational Study
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- VERIS HEALTH INCIndustry (pharma, biotech, devices)
- Collaborators
- National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), The Ohio State University Comprehensive Cancer Center
- Study start
- 11 Mar 2026 (actual)
- Primary completion
- 30 Nov 2027 (estimated)
- Study completion
- 30 Nov 2027 (estimated)
- First posted
- 9 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The proposed study aims to optimize and validate the Veris Cancer Care Platform for the needs of medically underserved cancer patients receiving outpatient cancer therapy. The Veris Health platform is a remote patient monitoring and communication system designed to bridge the gap between clinical visits and provide oncology care teams with objective data during high-risk periods.
This study will specifically focus on optimizing the Veris Health platform for patients with language barriers, limited access to technology, and socioeconomic disparities. By incorporating user-centered design and working closely with community health centers, the research team will ensure that the platform is culturally and linguistically appropriate, easy to use, and accessible for all patients.
The study will use a mixed-methods approach to validate the effectiveness of the optimized platform, including quantitative data analysis and qualitative interviews with patients and healthcare providers. The goal is to demonstrate the potential for the Veris Health platform to improve outcomes for vulnerable populations by reducing hospitalizations, emergency department visits, and the economic burden of cancer care.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 24 Weeks
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Main Phase group | – | Other: Veris Health Inc. ApplicationAll participating subject utilizing the Veris Health app will complete all study health measurements with a 24 week period on the Veris Health app as well as participate in interviews and focus groups. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Underserved population undergoing Cancer treatment with at least one on the following barriers to healthcare access: Spanish as primary language, uninsured, insured with Medicaid, dual eligible for Medicare and Medicaid.
Key inclusion criteria (5 listed)
- Adults > 18 years old
- Diagnosis of cancer
- ECOG Performance Status of 0-2
- Undergoing or initiating systemic anticancer therapy
- Able to utilize and interact with a mobile application and in-home devices for physiological monitoring. Have at least one of the following barriers to healthcare access: Spanish as primary language, uninsured, insured with Medicaid, dual eligible for Medicare and Medicaid
Key exclusion criteria (1 listed)
- -N/A
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Veris Health Inc. ApplicationVeris Health offers at-home devices to monitor multiple physiological parameters, including temperature, heart rate, oxygen saturation, blood pressure, weight, and activity (step count). Patients are provided with a home cellular hub that is already paired to peripheral devices via Bluetooth. The hub communicates with all devices and the local cellular network out-of-the-box, and data is automatically sent via cellular network to the Veris Health backend database, making it easy for patients to use the system. Patients are responsible for taking their vital sign measurements daily. The devices automatically send the measurement data to the Veris Health HIPAA compliant, secure cloud server via the preconnected cellular hub. | Other | Main Phase group |
Primary outcome
Usability of the Veris Health Cancer Care Platform
Time frame: 5 Months
Usability of the Veris Health Cancer Care platform as assessed by the Software Usability Measurement Inventory (SUMI) among patients, caretakers, and healthcare teams. Measure: SUMI total and domain scores Time Frame: During study participation
Product Design Usability and Acceptability
Time frame: 5 Months
Ease of use, accessibility, and acceptability of the Veris Health Cancer Care platform based on A/B testing of product design features. Measure: Comparative usability metrics (e.g., task completion success, user preference) Time Frame: During study participation
User Needs and Preferences
Time frame: 5 Months
User-identified needs, preferences, and barriers to use of the Veris Health Cancer Care platform. Measure: Qualitative themes derived from user interviews and focus groups Time Frame: During study participation
3 secondary outcomes
Health-Related Quality of Life (HRQL)
Time frame: 5 Months
Symptom Burden of Cancer Treatment Side Effects
Time frame: 5 Months
Cancer Treatment Adherence and Duration
Time frame: 5 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Sep 2026.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer Care Recipient and Observational Study, run by VERIS HEALTH INC at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Brian deGuzman MD COO (917-813-1828, bjd@verishealth.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Usability of the Veris Health Cancer Care Platform (time frame: 5 Months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2026.